CIS Pharma initiates a new R&D program on antibody-radionuclide conjugates
Bubendorf, Switzerland, Tuesday, July 10, 2018 - Over the course of the past months, CIS Pharma has developed concepts and strategies to conjugate radioisotopes onto its polymer-drug carriers. First syntheses [...]